Progress in Breast Cancer: Overview : Research in Breast Cancer: Frontiers in Genomics, Biology, and Clinical InvestigationARTEAGA, Carlos L.Clinical cancer research (Print). 2013, Vol 19, Num 23, pp 6353-6359, issn 1078-0432, 7 p.Article

Foundations of molecular therapies in breast carcinomaARTEAGA, Carlos L.Journal of mammary gland biology and neoplasia. 1999, Vol 4, Num 4, issn 1083-3021, 91 p.Serial Issue

Erlotinib (Tarceva): Potent HER1/Epidermal growth factor receptor inhibitionARTEAGA, Carlos L.Seminars in oncology. 2003, Vol 30, Num 3, issn 0093-7754, 54 p., SUP7Serial Issue

Epidermal Growth Factor Receptor-Targeted Approaches for Anticancer Therapy: Focus on ZD1839ARTEAGA, Carlos L.Drugs (Basel). 2000, Vol 60, issn 0012-6667, 46 p., SUP1Serial Issue

New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs AvailableABRAMSON, Vandana; ARTEAGA, Carlos L.Clinical cancer research (Print). 2011, Vol 17, Num 5, pp 952-958, issn 1078-0432, 7 p.Article

Critical update and emerging trends in epidermal growth factor receptor targeting in cancerBASELGA, José; ARTEAGA, Carlos L.Journal of clinical oncology. 2005, Vol 23, Num 11, pp 2445-2459, issn 0732-183X, 15 p.Article

Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: Implications for drug development and practicesARTEAGA, Carlos L; BASELGA, Jose.Clinical cancer research. 2003, Vol 9, Num 5, pp 1579-1589, issn 1078-0432, 11 p.Article

Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva)HIDALGO, Manuel; BLOEDOW, Duane.Seminars in oncology. 2003, Vol 30, Num 3, pp 25-33, issn 0093-7754, 9 p., SUP7Article

Erlotinib (Tarceva): An update on the clinical trial programHERBST, Roy S.Seminars in oncology. 2003, Vol 30, Num 3, pp 34-46, issn 0093-7754, 13 p., SUP7Article

Integrin function in breast carcinoma progressionSHAW, L. M.Journal of mammary gland biology and neoplasia. 1999, Vol 4, Num 4, pp 367-376, issn 1083-3021Article

Optimal Targeting of HER2-PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical ImplicationsREXER, Brent N; ARTEAGA, Carlos L.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 13, pp 3817-3820, issn 0008-5472, 4 p.Article

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agentsROWINSKY, Eric K.Drugs (Basel). 2000, Vol 60, pp 1-14, issn 0012-6667, SUP1Article

The ErbB receptors as targets for breast cancer therapyALBANELL, J; BASELGA, J.Journal of mammary gland biology and neoplasia. 1999, Vol 4, Num 4, pp 337-351, issn 1083-3021Article

The epidermal growth factor receptor : From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasiaARTEAGA, Carlos L.Journal of clinical oncology. 2001, Vol 19, Num 18, pp 32s-40s, issn 0732-183X, SUPConference Paper

ZD1839 ('Iressa')^1,2 as an anticancer agentBASELGA, José; AVERBUCH, Steven D.Drugs (Basel). 2000, Vol 60, pp 33-40, issn 0012-6667, SUP1Article

Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancerARTEAGA, Carlos L; TRUICA, Cristina I.Seminars in oncology. 2004, Vol 31, Num 1, pp 3-8, issn 0093-7754, 6 p., SUP3Article

Preclinical studies with erlotinib (Tarceva)AKITA, Robert W; SLIWKOWSKI, Mark X.Seminars in oncology. 2003, Vol 30, Num 3, pp 15-24, issn 0093-7754, 10 p., SUP7Article

Cell cycle checkpoints as therapeutic targetsSTEWART, Z. A; PIETENPOL, J. A.Journal of mammary gland biology and neoplasia. 1999, Vol 4, Num 4, pp 389-400, issn 1083-3021Article

The estrogen receptor : A logical target for the prevention of breast cancer with antiestrogensTONETTI, D. A; JORDAN, V. C.Journal of mammary gland biology and neoplasia. 1999, Vol 4, Num 4, pp 401-413, issn 1083-3021Article

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast CancerMILLER, Todd W; BALKO, Justin M; ARTEAGA, Carlos L et al.Journal of clinical oncology. 2011, Vol 29, Num 33, pp 4452-4461, issn 0732-183X, 10 p.Article

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaARTEAGA, Carlos L.Seminars in oncology. 2002, Vol 29, Num 5, pp 3-9, issn 0093-7754, SUP14Conference Paper

The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumorsRITTER, Christoph A; ARTEAGA, Carlos L.Seminars in oncology. 2003, Vol 30, Num 1, pp 3-11, issn 0093-7754, 9 p., SUP1Article

Proapoptotic activity of cell-permeable anti-akt single-chain antibodiesSHIN, Incheol; EDL, Jeniffer; BISWAS, Swati et al.Cancer research (Baltimore). 2005, Vol 65, Num 7, pp 2815-2824, issn 0008-5472, 10 p.Article

When Tumor Suppressor TGFβ Meets the HER2 (ERBB2) OncogeneCHOW, Amy; ARTEAGA, Carlos L; EMILY WANG, Shizhen et al.Journal of mammary gland biology and neoplasia. 2011, Vol 16, Num 2, pp 81-88, issn 1083-3021, 8 p.Article

Knockdown of the Transforming Growth Factor-β Type III Receptor Impairs Motility and Invasion of Metastatic Cancer CellsCRISWELL, Tracy L; DUMONT, Nancy; BARNETT, Joey V et al.Cancer research (Chicago, Ill.). 2008, Vol 68, Num 18, pp 7304-7312, issn 0008-5472, 9 p.Article